Evidence map›Paper›PMID 27906134›Full record

ArticleOpen biology2016

Tumour-suppressor microRNAs regulate ovarian cancer cell physical properties and invasive behaviour.

Clara K Chan, Yinghong Pan, Kendra Nyberg, Marco A Marra, Emilia L Lim, Steven J M Jones, Dianna Maar, Ewan A Gibb, Preethi H Gunaratne, A Gordon Robertson and 1 more

Open access · goldAbstract read
In one paragraph

Article in Open biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Clara K ChanDepartment of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA clarachan27@gmail.com.ORCID 0000-0003-2832-4333
Yinghong PanDepartment of Biochemistry and Biology, University of Houston, Houston, TX, USA.
Kendra NybergDepartment of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA.
Marco A MarraBritish Columbia Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
Emilia L LimBritish Columbia Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
Steven J M JonesBritish Columbia Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
Dianna MaarBio-Rad Laboratories, The Digital Biology Center, Pleasanton, CA, USA.
Ewan A GibbBritish Columbia Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
Preethi H GunaratneDepartment of Biochemistry and Biology, University of Houston, Houston, TX, USA.
A Gordon RobertsonBritish Columbia Cancer Agency, Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
Amy C RowatDepartment of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA, USA rowat@ucla.edu.
Canada's Michael Smith Genome Sciences Centre · CAUniversity of California, Los Angeles · USUniversity of British Columbia · CABaylor College of Medicine · USBio-Rad (United States) · USUniversity of Houston · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9M
NCATS NIH HHS UL1 TR000124NCI NIH HHS P30 CA016042NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

The activities of pathways that regulate malignant transformation can be influenced by microRNAs (miRs). Recently, we showed that increased expression of five tumour-suppressor miRs, miR-508-3p, miR-508-5p, miR-509-3p, miR-509-5p and miR-130b-3p, correlate with improved clinical outcomes in human ovarian cancer patients, and that miR-509-3p attenuates invasion of ovarian cancer cell lines. Here, we investigate the mechanism underlying this reduced invasive potential by assessing the impact of these five miRs on the physical properties of cells. Human ovarian cancer cells (HEYA8, OVCAR8) that are transfected with miR mimics representing these five miRs exhibit decreased invasion through collagen matrices, increased cell size and reduced deformability as measured by microfiltration and microfluidic assays. To understand the molecular basis of altered invasion and deformability induced by these miRs, we use predicted and validated mRNA targets that encode structural and signalling proteins that regulate cell mechanical properties. Combined with analysis of gene transcripts by real-time PCR and image analysis of F-actin in single cells, our results suggest that these tumour-suppressor miRs may alter cell physical properties by regulating the actin cytoskeleton. Our findings provide biophysical insights into how tumour-suppressor miRs can regulate the invasive behaviour of ovarian cancer cells, and identify potential therapeutic targets that may be implicated in ovarian cancer progression.

Indexed as

Up-RegulationActin CytoskeletonCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMicroRNAsNeoplasm InvasivenessOvarian NeoplasmsSignal TransductionMicroRNAsactin cytoskeletoncell deformabilitymicrofiltrationmicrofluidicstumour cell invasion

Identifiers

PMID27906134
PMCPMC5133448
OpenAlexW2558177455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.